These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 3971844)

  • 1. Rarity of a marked "dawn phenomenon" in diabetic subjects treated by continuous subcutaneous insulin infusion.
    Bending JJ; Pickup JC; Collins AC; Keen H
    Diabetes Care; 1985; 8(1):28-33. PubMed ID: 3971844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twenty-Four Hour Fasting (Basal Rate) Tests to Achieve Custom-Tailored, Hour-by-Hour Basal Insulin Infusion Rates in Patients With Type 1 Diabetes Using Insulin Pumps (CSII).
    Nauck MA; Lindmeyer AM; Mathieu C; Meier JJ
    J Diabetes Sci Technol; 2021 Mar; 15(2):360-370. PubMed ID: 31633384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis and prevention of the dawn phenomenon in diabetic patients treated with CSII.
    Koivisto VA; Yki-Järvinen H; Helve E; Karonen SL; Pelkonen R
    Diabetes; 1986 Jan; 35(1):78-82. PubMed ID: 3510143
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of asymptomatic nocturnal hypoglycemia on glycemic control in diabetes mellitus.
    Perriello G; De Feo P; Torlone E; Calcinaro F; Ventura MM; Basta G; Santeusanio F; Brunetti P; Gerich JE; Bolli GB
    N Engl J Med; 1988 Nov; 319(19):1233-9. PubMed ID: 3054544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with Type 1 Diabetes Treated with Insulin Pumps Need Widely Heterogeneous Basal Rate Profiles Ranging from Negligible to Pronounced Diurnal Variability.
    Lindmeyer AM; Meier JJ; Nauck MA
    J Diabetes Sci Technol; 2021 Nov; 15(6):1262-1272. PubMed ID: 32806947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Insulin Pump Therapy and Multiple Daily Injections Insulin Regimen in Patients with Type 1 Diabetes During Ramadan Fasting.
    Alamoudi R; Alsubaiee M; Alqarni A; Saleh Y; Aljaser S; Salam A; Eledrisi M
    Diabetes Technol Ther; 2017 Jun; 19(6):349-354. PubMed ID: 28296467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nocturnal blood glucose control in type I diabetes mellitus.
    Bolli GB; Perriello G; Fanelli CG; De Feo P
    Diabetes Care; 1993 Dec; 16 Suppl 3():71-89. PubMed ID: 8299480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
    Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
    Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes.
    Pickup J; Keen H
    Diabetes Care; 2002 Mar; 25(3):593-8. PubMed ID: 11874953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early-morning hyperglycemia in diabetic individuals treated with continuous subcutaneous insulin infusion.
    Geffner ME; Frank HJ; Kaplan SA; Lippe BM; Levin SR
    Diabetes Care; 1983; 6(2):135-9. PubMed ID: 6682750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Blood sugar control in diabetic patients bearing microinfusors: the importance of the dawn phenomenon].
    Consoli A; Capani F; Vitacolonna E; Sensi S
    Boll Soc Ital Biol Sper; 1984 Sep; 60(9):1685-9. PubMed ID: 6395872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nocturnal blood glucose and IGFBP-1 changes in type 1 diabetes: Differences in the dawn phenomenon between insulin regimens.
    Yagasaki H; Kobayashi K; Saitou T; Nagamine K; Mitsui Y; Mochizuki M; Kobayashi K; Cho H; Ohyama K; Amemiya S; Nakazawa S
    Exp Clin Endocrinol Diabetes; 2010 Mar; 118(3):195-9. PubMed ID: 19834874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.
    Attia N; Jones TW; Holcombe J; Tamborlane WV
    Diabetes Care; 1998 May; 21(5):817-21. PubMed ID: 9589247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Continuous subcutaneous insulin infusion (CSII) in treating young diabetic patients].
    Buczkowska EO; Dworzecki T; Wiedermann G; Malanowicz B; Szot D
    Przegl Lek; 2005; 62(1):49-53. PubMed ID: 16053222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of plasma glucose and plasma free insulin during CSII and intensified conventional insulin therapy.
    Buysschaert M; Marchand E; Ketelslegers JM; Lambert AE
    Diabetes Care; 1983; 6(1):1-5. PubMed ID: 6341010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overnight metabolic control with bedtime injection of intermediate-acting insulin or continuous subcutaneous insulin infusion.
    Olsson PO; Arnqvist H; Von Schenck H; Ottosson AM
    Diabetes Care; 1987; 10(6):702-6. PubMed ID: 3322726
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic response to fasting exercise in adolescent insulin-dependent diabetic subjects treated with continuous subcutaneous insulin infusion and intensive conventional therapy.
    Schiffrin A; Parikh S; Marliss EB; Desrosiers MM
    Diabetes Care; 1984; 7(3):255-60. PubMed ID: 6376018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations in insulin clearance and hepatic blood flow during the night do not contribute to the 'dawn phenomenon' in type 1 diabetes.
    Widmer A; Keller U; Pasquel M; Berger W
    Horm Res; 1988; 29(5-6):197-201. PubMed ID: 3065206
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic alterations after a two-hour nocturnal interruption of a continuous subcutaneous insulin infusion.
    Scheen A; Castillo M; Jandrain B; Krzentowski G; Henrivaux P; Luyckx AS; Lefèbvre PJ
    Diabetes Care; 1984; 7(4):338-42. PubMed ID: 6381007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 2-way cross-over, open-labeled trial to compare efficacy and safety of insulin Aspart and Novolin R delivered with CSII in 21 Chinese diabetic patients.
    Bi YF; Zhao LB; Li XY; Wang WQ; Sun SY; Chen YH; Hong J; Su TW; Liu JM; Ning G
    Chin Med J (Engl); 2007 Oct; 120(19):1700-3. PubMed ID: 17935674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.